Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments (Lizette Chapman/Bloomberg)
on
Get link
Facebook
Twitter
Pinterest
Email
Other Apps
Lizette Chapman / Bloomberg:
Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments — Palantir Technologies Inc. won a deal with the U.S. Food and Drug Administration to help power drug reviews and inspections … http://dlvr.it/RnBYrz
Comments
Post a Comment